IP Library › Granted Patent US 11,739,044
Granted Patent B2
US 11,739,044 · App. 17/183,324 · Granted Aug 29, 2023

Method for synthesizing artepillin C and intermediate compound thereof

Inventors: Ming-Hsi Chuang (Zhubei, TW); Lin-Hsiang Chuang (Zhubei, TW); Ming-Hsuan Lu (Zhubei, TW); Wen-Peng Shen (Zhubei, TW); Yun-Chen Lin (Zhubei, TW); Chi-Hsuan Chuang (Zhubei, TW)
Assignee: GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.
C07C51/09C07C51/42C07C59/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,739,044
App. No.
17/183,324
Granted
Aug 29, 2023
Kind
B2
Abstract

The present invention relates to a method for synthesizing artepillin C and a synthetic method for synthesizing an intermediate compound for use in preparing artepillin C. The structural formula of artepillin C is shown in the following formula (IV), and the intermediate compound is shown in the following formula (II). The synthesis method includes the following steps: a first reaction step: in the presence of a base initiator, a compound A shown in formula I and 3,3-dimethylallyl bromide are mixed, the reaction continues for a first reaction time and is stopped to generate an intermediate of artepillin C shown in formula II; and a second reaction step: the intermediate of artepillin C is dissolved in an aqueous alcohol solution and then mixed with an alkali metal salt, and the reaction continues for a second reaction time to generate artepillin C.

Claims (23)

1. A method for synthesizing artepillin C, which comprises the following steps:

a first reaction step: in the presence of a base initiator, a compound A shown in formula I and 3,3-dimethylallyl bromide are mixed in a solvent including at least one selected from toluene, dimethylformamide, tetrahydrofuran, and dimethylsulfoxide to lead a first reaction in an ice bath continuously for 72 hrs, and then water is poured into the reaction solution to stop the reaction to generate a first reaction product, which comprises an intermediate of artepillin C shown in formula II,

in which R is C 1-6 alkyl, and

a second reaction step: the intermediate of artepillin C is dissolved in an aqueous alcohol solution and then mixed with an alkali metal salt, and the reaction continues for a second reaction time to generate a second reaction product, which comprises artepillin C shown in formula IV;

wherein

in the first reaction step, the molar ratio of the compound A to 3,3-dimethylallyl bromide is 1:2, the molar ratio of the compound A to the base initiator is 1:2, and the first reaction is carried out in a vacuum environment with argon; and

in the second reaction step, the second reaction time is in the range of 8 h to 20 h.

2. The method for synthesizing artepillin C of claim 1 , wherein the base initiator is sodium hydride.

3. The method for synthesizing artepillin C of claim 1 , wherein after the first reaction step, a first purification step is further comprised:

in an acidic environment, the first reaction product is extracted with ethyl acetate to obtain a first crude extract, and then the first crude extract is purified by normal phase column chromatography to obtain the intermediate of artepillin C with a purity of above 95%.

4. The method for synthesizing artepillin C of claim 3 , wherein the product yield of the intermediate of artepillin C after purification is above 35%.

5. The method for synthesizing artepillin C of claim 1 , wherein after the second reaction step, a second purification step is further comprised:

in an acidic environment, the second reaction product is extracted with ethyl acetate to obtain a second crude extract, and then the second crude extract is purified by normal phase column chromatography to obtain artepillin C with a purity of above 95%.

6. The method for synthesizing artepillin C of claim 5 , wherein the product yield of artepillin C after purification is above 35%.

7. A method for synthesizing an intermediate of artepillin C, which comprises the following steps:

a reaction step: in the presence of a base initiator, a compound A shown in formula I and 3,3-dimethylallyl bromide are mixed in a solvent including at least one selected from toluene, dimethylformamide, tetrahydrofuran, and dimethylsulfoxide to lead a reaction in an ice bath continuously for 72 hrs, and then water is poured into the reaction solution to stop the reaction to generate an intermediate of artepillin C shown in formula II;

in which R is C 1-6 alkyl; wherein

the molar ratio of the compound A to 3,3-dimethylallyl bromide is 1:2, the molar ratio of the compound A to the base initiator is 1:2; and

the reaction is carried out in a vacuum environment with argon.

8. The method for synthesizing an intermediate of artepillin C of claim 7 , wherein after the reaction step, a purification step is further comprised:

in an acidic environment, the reaction mixture obtained by completing the reaction step is extracted with ethyl acetate to obtain a crude extract, and then the crude extract is purified by normal phase column chromatography to obtain the intermediate of artepillin C with a purity of above 95%.

9. The method for synthesizing an intermediate of artepillin C of claim 7 , wherein the base initiator is sodium hydride.

10. The method for synthesizing an intermediate of artepillin C of claim 7 , wherein the product yield of the intermediate of artepillin C is above 35%.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2021
From: ULTRA-MICRORIGIN BIOMEDICAL TECHNOLOGY CO., LTD.
To: GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.
Reel/Frame 056436/0075 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2021
From: CHUANG, MING-HSI; CHUANG, LIN-HSIANG; LU, MING-HSUAN; SHEN, WEN-PENG; LIN, YUN-CHEN; CHUANG, CHI-HSUAN
To: ULTRA-MICRORIGIN BIOMEDICAL TECHNOLOGY CO., LTD.
Reel/Frame 055379/0049 →
Priority Claims (1)
TW 109133304 · Sep 25, 2020 · national
Continuity (1)
Related Publication 20220098139A1 · Mar 31, 2022